Former Onyx CEO Coles resurfaces to fund, lead Yumanity
This article was originally published in Scrip
Executive Summary
Tony Coles moved on long ago from proteasome inhibitors for blood cancers after the former Onyx Pharmaceuticals chairman and CEO sold the company to Amgen in October 2013 for $10bn and he's finally revealed where he will focus his attention next: protein misfolding in neurodegenerative diseases.